We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App





Procter & Gamble’s Novel Fully Injection-Molded Polypropylene Nasal Swab Improves Speed of COVID-19 Testing

By LabMedica International staff writers
Posted on 25 Jan 2021
Print article
Image: Rhinostics Standard Nasal Swab (Photo courtesy of Business Wire)
Image: Rhinostics Standard Nasal Swab (Photo courtesy of Business Wire)
A novel polypropylene nasal swab developed for COVID-19 testing that allows for easy collection from the front of the nose and provides sample concentration of up to 30 fold over other swabs in viral transport media is likely to positively impact testing availability.

Procter & Gamble (P&G; Cincinnati, OH, USA) and Rhinostics Inc. (Cambridge, MA, USA), a Harvard spin-out company, have partnered to develop the nasal swab that improves the speed of testing and adds additional swab capacity for COVID-19 testing. The fully injection-molded polypropylene nasal swab has been developed by iMFLUX, a subsidiary of P&G, which is licensing its novel nasal swab to Rhinostics to launch and bring to the clinical laboratory market.

P&G developed the swab as part of its commitment to help communities address supply shortages and to bring creative solutions to bear on the challenges facing laboratories and supply chains during the COVID-19 pandemic. The project was a collaboration between resources from P&G’s Personal Health Care business and iMFLUX, a subsidiary focused on mold design and process technology innovation for the plastics injection molding market. Swabs continue to be in short supply and are critical to fighting the COVID-19 pandemic. The companies believe the nasal swab’s unique features make it a better material choice for both PCR and antigen-based assays. These swabs reduce handling and lab processing cycle time and increase lab capacity as new home collection kits expand rapidly into the virus detection market.

Rhinostics plans on registering the P&G polypropylene nasal swab as a Class I Exempt medical device and will pursue Emergency Use Authorization for home collection with rPT-PCR testing, the gold standard for detection of SARS-CoV-2 infection. This licensing agreement has the potential to provide relief to the constrained market, expedite test results and be a solution for future testing needs, like influenza.

“We are proud to see the P&G developed nasal swab come to market through Rhinostics efforts. When we began this program, our intention was simply to help relieve bottlenecks in COVID-19 swab supply and bring a novel collection device to bear on the problem,” said Mary Wagner, SVP at P&G and CEO of iMFLUX.

“P&G and iMFLUX have been vital partners in helping Rhinostics launch the manufacturing of its nasal swab collection products. We believe there is a significant opportunity to bring new collection devices like the P&G nasal swab to clinical laboratory workflow. Not only does the nasal swab production help to relieve supply chain bottlenecks, the new design and polypropylene materials allows for comfortable collection and sample concentration due to dry shipment and improved release of viral particles. We are excited to bring this innovation to the clinical laboratory market,” says Cheri Walker, Chief Executive Officer of Rhinostics, “We look forward to continuing to work with the iMFLUX team to develop molds across our product lines.”

Related Links:
Procter & Gamble
Rhinostics Inc.


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chagas Disease Test
LIAISON Chagas
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.